Review articlePublished 3 Mar 2015
Hyp-O-besity: Unmet Challenge in Management of Type 2 Diabetes Mellitus and Cardiovascular Risk
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Glycaemic control is often disturbed by iatrogenic hypoglycaemia as a result of intensive and can be a major barrier to optimal glycaemic management. This risk of hypoglycaemia acts like a deterrent to the patient from achieving euglycaemia. The fear of hypoglycaemia leads to “defensive snacking” which further disrupts achievement of euglycaemia and leads to weight gain. Obesity by itself carries a major risk for adverse cardiovascular outcomes and coupled with hypoglycaemia significantly increases the cardiovascular risk in patients with diabetes. “Hyp-obesity” is a new term that effectively conveys the present challenges in achieving euglycaemia due to hypoglycaemia and obesity and would help facilitate therapeutic strategies to optimise diabetes management. Newer drugs targeting the incretin pathway such as glucagon-like peptide-1 (GLP-1) mimetic and dipeptidyl peptidase-4 (DPP-4) inhibitors would be beneficial in minimising the risk of hypoglycaemia and obesity.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectCardiology
- SubjectDiabetes & Endocrinology
- BylineArticles whose byline prints “Ambady Ramachandran”
- BylineArticles whose byline prints “Subramanium Venkatraman”
- BylineArticles whose byline prints “Anand Moses”
- BylineArticles whose byline prints “Gunupati Vijayakumar”